Reviews
“Zebrafish: From Disease
Modeling to Drug Discovery”
Current Opinion in Drug Discovery & Development (2003) 6:218-223.
“Cancer genetics and
drug discovery in the zebrafish”
Nature Reviews Cancer (2003) 3:533-539.
“High-throughput target validation
in model organisms”
Drug Discovery Today: Targets (2004) 3:191-197.
"Zebrafish
assays for drug toxicity screening"
Exerpt opinion on Drug Metabolism and Toxicology (2006) 2:231-240
Application Notes
“High Throughput
in vivo screening for anti-angiogenic compounds using the
Z-TagSM Angiogenesis Assay”
Nature Methods Application Note (2008)
“High
throughput Imaging of Zebrafish Embryos for Drug Discovery”
Blueshift Biotechnologies Application Note (2008).
Primary literature
“Genetic Analysis of Digestive
Physiology Using Fluorescent Phospholipid Reporters”
Science (2001) 292:1385-1388.
“Rapid Analysis
of Angiogenesis Drugs in a Live Fluorescent Zebrafish Assay”
Arteriosclerosis, Thrombosis and Vascular Biology (2003) 23:911-912.
“Drugs
that induce repolarization abnormalities cause bradycardia in zebrafish”
Circulation (2003) 107:1355-1358.
“BRAF mutations are
sufficient to promote nevi formation and cooperate with p53 in the genesis
of melanoma”
Current Biology (2005) 15:249-254.
“Lessons from ‘‘Lower’’ Organisms: What Worms, Flies, and Zebrafish Can
Teach Us about Human Energy Metabolism”
PLoS Genetics (2007) 3:2037-2048.
“Cell Lineage Specific-Expression in Transgenic Zebrafish’’
US Patent No 6,380,458 (2002)
“Inhibition of Gene Expression using Polynucleotide Analogs’’
US Patent No. 6,867,349 (2005)
“Automated, Quantitative Screening Assay for Antiangiogenic Compounds Using Transgenic Zebrafish”
Cancer Res (2007) 67: 11386-11392.